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http://dx.doi.org/10.1016/j.chembiol.2013.02.008John Scott has just finished applying new
microscopic hookworm larvae via
a bandage on his arm. ‘‘It is itching
already,’’ he says, cheerily. Scott, a
retired special education teacher and
moderator of the Helminthic Therapy
Forum (http://health.groups.yahoo.com/
group/helminthictherapy) suffered from
allergies and the intestinal inflammation
of Crohn’s disease since childhood.
Scott’s remaining option was surgery.
He volunteered to be infected with
hookworms in the 2009 University of
Nottingham trials. His symptoms went
into remission and he could eat normalParasitic nematodes called helminths can calm the symptoms
of certain autoimmune diseases and allergies.food for the first time in years, but when
Scott was ‘‘dewormed’’ at the trial’s
conclusion, his symptoms returned. With
the assent of his physician, Scott ordered
some hookworms from an online parasite
purveyor and has assiduously maintained
his personal parasite colony ever since,
attributing them with keeping his symp-
toms in check.
Do-it-yourself parasite husbandry,
however, may soon be outmoded. In
the near future, you may be able to
get parasites with a prescription. In
the past decade or two, accumulat-
ing clues from human and animal
studies suggest that parasitic nema-
todes called helminths can calm the
symptoms of certain autoimmune dis-
eases and allergies. Burlington, Massa-
chusetts, based Coronado Biosciences
(http://www.coronadobiosciences.com)
is commercializing GMP-certified pig
whipworm (Trichuris suis), dubbed
TSO, and has commenced FDA clinical
trials for a variety of autoimmune
disorders.A Very Long Engagement
Millionsofdollarsarespentonpublichealth
programsaround theworld to eliminate the
misery of parasites. The World Health
Organization, in its 2012 report ‘‘Research
Priorities for Helminth Infections’’ (World
Health Organization, 2012) estimates that
over a billion people in sub-Saharan Africa,
Asia, and the Americas suffer from para-
sites, but the report states, with grudging
admiration, that ‘‘the emerging theme in
basic research is the realization that the
host-parasite immunological relationship
is interactive, and that helminths are
masterful immunoregulators.’’According to the hygiene hypothesis,
public health measures like sewers, clean
water, and food have created an environ-
ment so clean that some people’s
immune systems go out of whack. Only
recently have parasites stopped being
ubiquitous, at least in the developed
world. The unintended consequence is
a rise in autoimmune disease and aller-
gies, according to Joel Weinstock, chief
of the Division of Gastroenterology and
Hepatology at Tufts NewEnglandMedical
Center and an advisor to Coronado
Biosciences. At his former position at the
University of Iowa, Weinstock and fellow
gastroenterologists David E. Elliott and
Robert Summers parsed the effects of
helminths on the immune circuitry of
various mouse models for inflammatory
bowel disease (IBD). According to
Weinstock, the worms can be considered
to be a living vaccine. Weinstock’s lab is
forming an academic consortium to char-
acterize helminths and their effects.
Whether the eventual result will be a
transgenic worm or if the molecules thatChemistry & Biology 20, February 21, 2013helminths secrete can be reproduced as
drugs is to be determined.
Widening Woburn’s Manufacturing
Base
Coronado Biosciences’ T. suis ova
(CNDO-201) has a favorable safety profile
because it is a pig parasite. Unlike other
intestinal helminths that enter the host as
a worm, T. suis eggs only hatch once
they enter the human gut; they last a few
weeks and then expire. According to
Bobby W. Sandage, Coronado president
and director, data accumulated on 300
patients showed that about a third com-
plained of mild GI symptoms such as diar-
rhea andcramping. After the first day, TSO
was generally well tolerated. TSO doesn’t
cause resistance, according to Sandage,
whereas 50% of the people who take
Remicade or Humira for IBD develop
resistance, making the drugs ineffective.
TSO, however, also has its drawbacks.
In a 2011 Danish allergic rhinitis study, 49
adults who ingested 2500 T. suis eggs
every 3 weeks for 4 months experienced
a 3- to 19-fold higher rate of episodes of
flatulence, diarrhea, and abdominal pain
than 47 placebo subjects. Reactions
lasted up to 2 weeks; most happened in
the first half of the study (Bager et al.,
2011).
Coronado’s TRUST-I (TRichUris Suis
ova Trial), a phase 2 clinical trial in patients
with Crohn’s disease, began in August
2012 and is expected to conclude in the
second half of 2013. Phase 2 trials are
also being conducted in ulcerative colitis
and multiple sclerosis. Coronado is also
investigating TSO for adults with inflam-
mation linked to autism. TSO therapies
for psoriasis, type I diabetes, psoriatic
arthritis, and rheumatoid arthritis are in
preclinical development.
Coronado’s T. suis ova are grown in a
master ovabank, fully characterized, and
then inoculated into a special breed ofª2013 Elsevier Ltd All rights reserved 135
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a batch of up to 100 million eggs. The
eggs are isolated from pig feces and
sent to partner OvaMed GmbH (where
a company founder had persuaded
European regulators to approvemedicinal
maggots for wound healing) to be steril-
ized, incubated, tested for contami-
nants, and counted. The end result is
a vial with microscopic eggs in suspen-
sion, like bubble tea. Doses range from
250 eggs per 15 ml to 7,500 eggs per
15 ml. Coronado will set up an egg pro-
cessing facility in nearby Woburn later
this year.
CNDO 109, a product to stimulate
production of tumor-activated natural
killer (NK) cells in relapsed acute myeloid
leukemia (AML) and solid tumors is in
a phase 1/2 trial—Coronado Biosciences
is first conducting a dose escalation trial,
thenanefficacy trial. Aproduct formultiple
myeloma is in preclinical development.
As of January 2013, Coronado had
$150 million in market capitalization. The
company went public in September
2011 through a self-registration process
known as Form 10. Coronado was listed
on NASDAQ in December 2011, but didn’t
do an IPO. The company’s June 2012 first
public offering netted $26.5 million.
OvaMed licensed the T. suis intellectual
property from the University of Iowa, part-
nering with Coronado to cover North and
South America and Japan for all indica-
tions and with Dr. Falk Pharma (http://
www.drfalkpharma.de) for gastrointes-
tinal-only indications in Europe. Accord-
ing to Sandage, the autoimmune and
cancer areas are multibillion dollar
markets. But it is too early to determine
the cost of TSO treatment.
Not All Worms Are Equal
The hygiene hypothesis is almost impos-
sible to prove, according to Dr. William
E. Secor, a schistosomiasis researcher
at the Centers for Disease Control and
Prevention. ‘‘You have evidence for it,
but you couldn’t actually do a real exper-
iment on people,’’ says Secor. ‘‘Any time
you are dealing with people, there are
so many influences.’’ Bottom line, what
matters are the clinical trials.
‘‘The field is small,’’ says Secor. ‘‘Not
that many people make their living off of
studying worms. Among the people that
do it, it is recognized pretty well that not
all worms are created equal.’’ According136 Chemistry & Biology 20, February 21, 201to Secor, the helminth effect can either
be ‘‘good’’ or ‘‘bad’’ depending on the
type of worm and the coinfection or
syndrome. People who are coinfected
with parasites may respond poorly to
vaccines and may be more vulnerable to
diseases like HIV ormalaria. ‘‘The immune
response that is induced by worms can
influence other immune responses and
diseases like inflammatory bowel disease,
Crohn’s disease, multiple sclerosis—
those are immune-mediated patholo-
gies,’’ says Secor. According to Secor,
these autoimmune diseases are associ-
ated with a T-helper 1 (TH1) immune
response. Helminths induce a T-helper 2
(TH2) immune response. But as TH1 cells
and TH2 cells cross-regulate each other,
some cytokines are produced, particu-
larly IL-10, which dampen the TH1
response and can alleviate some symp-
toms. The Th2 response depends on
the type of worm involved. In general,
the more tissue-invasive the worm, the
stronger the host’s Th2-type immune
response will be, and the weaker the Th1
response.
‘‘The typical Th2 response to intestinal
worm infections is ‘‘weep and sweep,’’
where the worm stimulates mucous
production that helps wash out the
worms,’’ says Secor. According to Secor,
helminth infection is localized and less
likely to induce immune response at unre-
lated sites compared to steroids or other
immunosuppressive drugs that have
systemic effects.
Keeping Up the Mucosal Layer
P’ng Loke, a parasitologist at New York
University Medical School, formerly
worked on mouse models. He was then
approached by a patient with refractory
ulcerative colitis who put his disease
in remission by infecting himself with
Trichuris trichiura (human whipworm)
and offered himself as a research subject.
Loke spent 5 years monitoring him with
colonoscopies and biopsies and found
alterations in his immune cells as well as
the bacteria inside his intestinal tract.
Perhaps, Loke wondered, helminths
ease symptoms of ulcerative colitis not
by regulating the immune response but
by affecting the intestinal mucus layer.
Loke is commencing a clinical trial
on ulcerative colitis using Coronado’s
T. suis. (Loke has been on the advisory
panel of the company, but has no3 ª2013 Elsevier Ltd All rights reservedfinancial interest.) It is a crossover trial
randomized between T. suis and placebo.
Patients will be treated in either the first
or the second round—an incentive for
recruitment, as participants will have to
undergo three colonoscopies. Patients
will be dosed with 2500 eggs every
2 weeks for a 12 week period before
crossing to the other branch. The trial is
designed to provide longitudinal dynamic
information on the group that gets the
TSO and then goes to placebo. It will
also screen for susceptibility genes for
IBD like NOD2 and ATG16L1, examine
intestinal microbiota, and mucosal
immune response. Loke’s team is collect-
ing fecal samples to determine the
bacteria in the gut lining. They will also
isolate DNA from pinch biopsies of tissue
from the colon, including the DNA from
the attached bacteria. People who have
taken TNF inhibitors like Remicade and
Humira will be excluded. ‘‘Both Crohn’s
disease and ulcerative colitis are thought
to be driven by an aberrant response
to intestinal flora,’’ Loke says. ‘‘It fits the
hypothesis, I guess.’’
Loke is interested in which patients
will respond to treatment. ‘‘Based on the
clinical trial that was done previously,
we expect about 50% of patients to
respond,’’ says Loke.
‘‘It is possible that helminth infection
may exacerbate ulcerative colitis symp-
toms in some patients by elevating the
TH2 response in the intestinal mucosa,’’
says Loke. While hookworms have a
narrow dosing window between thera-
peutic benefits and pathogenic side
effects, Coronado is using doses of up
to 7500 T. suis eggs. ‘‘It is astonishing,
really,’’ Loke says. ‘‘So far it doesn’t
seem to have any severe side effects.’’REFERENCES
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